FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118320211> ?p ?o ?g. }

• W2118320211 abstract "Background Vascular endothelial growth factor inhibitors such as bevacizumab, sorafenib, and sunitinib are utilized in the treatment of multiple cancers. Although these agents are associated with hypertension, there is a lack of evidence describing patterns of antihypertensive use in patients with vascular endothelial growth factor inhibitor-associated hypertension in a non-trial, “real-world” setting. Objective To describe the occurrence and severity of vascular endothelial growth factor inhibitor-associated hypertension, patterns of antihypertensive use and occurrence of cardiovascular complications in a non-trial population, and to describe patterns of initial antihypertensive therapy in patients developing hypertension during treatment with a vascular endothelial growth factor inhibitor. Methods This retrospective cohort study utilized claims data from the Medstat MarketScan Commercial Claims and Encounter database to identify patients with claims for a vascular endothelial growth factor inhibitor and a diagnosis of cancer using International Classification of Diseases, 9th Revision, Clinical Modification codes, Healthcare Common Procedure Coding System J-codes and National Drug Codes. The study period encompassed claims from one year before the patient’s first claim for a vascular endothelial growth factor inhibitor, and continued through one year after the initial vascular endothelial growth factor inhibitor claim. Patients meeting study criteria were classified into cohorts A1, patients with no hypertension throughout the study period; A2, patients without hypertension at baseline who developed hypertension after starting a vascular endothelial growth factor inhibitor; and cohort B, patients with hypertension prior to receiving a vascular endothelial growth factor inhibitor. We utilized medical and pharmacy claims data to describe the presence of hypertension, its severity, and the occurrence of cardiovascular complications throughout the study period. Initial antihypertensive use in cohort A2 was described. Results In all, 2177 patients met study criteria and were categorized into cohorts A1 (n = 708), A2 (n = 333) and B (n = 1136). Approximately 32% of patients without hypertension at baseline had claims suggestive for hypertension during the study period. Life-threatening (Grade 4) hypertension increased throughout the study period for cohorts A1, A2, and B, to 3.4%, 10.2%, and 16.4%, respectively ( p < 0.001 for all). Claims suggestive of Grade 3 hypertension occurred in more patients in cohort B (45.8%) than in cohort A2 (32.7%, p < 0.001). Cardiovascular complications occurred in 4.7%, 15.6%, and 22.7% of patients in cohorts A1, A2, and B, respectively. Initial antihypertensive agent selection did not impact the occurrence of cardiovascular complications in cohort A2. Conclusion Our study provides valuable insight into non-trial patterns of vascular endothelial growth factor inhibitor-associated hypertension occurrence and severity, and is consistent with prior claims analysis. Identification of optimal strategies to manage vascular endothelial growth factor inhibitor-associated hypertension remain to be clarified with the advent of more comprehensive data sets." @default.
• W2118320211 created "2016-06-24" @default.
• W2118320211 creator A5008381135 @default.
• W2118320211 creator A5014606922 @default.
• W2118320211 creator A5027368636 @default.
• W2118320211 creator A5056278530 @default.
• W2118320211 creator A5090647064 @default.
• W2118320211 date "2014-04-11" @default.
• W2118320211 modified "2023-09-23" @default.
• W2118320211 title "Claims analysis of hypertension occurrence, severity changes and patterns of antihypertensive use in cancer patients receiving vascular endothelial growth factor inhibitors" @default.
• W2118320211 cites W1965024282 @default.
• W2118320211 cites W1977379029 @default.
• W2118320211 cites W1983465663 @default.
• W2118320211 cites W2071433295 @default.
• W2118320211 cites W2119358583 @default.
• W2118320211 cites W2122724278 @default.
• W2118320211 cites W2125922540 @default.
• W2118320211 cites W2126970264 @default.
• W2118320211 cites W2143954917 @default.
• W2118320211 cites W2149049679 @default.
• W2118320211 cites W2614433098 @default.
• W2118320211 cites W4292172722 @default.
• W2118320211 doi "https://doi.org/10.1177/1078155214530177" @default.
• W2118320211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24727344" @default.
• W2118320211 hasPublicationYear "2014" @default.
• W2118320211 type Work @default.
• W2118320211 sameAs 2118320211 @default.
• W2118320211 citedByCount "3" @default.
• W2118320211 countsByYear W21183202112017 @default.
• W2118320211 countsByYear W21183202112020 @default.
• W2118320211 countsByYear W21183202112022 @default.
• W2118320211 crossrefType "journal-article" @default.
• W2118320211 hasAuthorship W2118320211A5008381135 @default.
• W2118320211 hasAuthorship W2118320211A5014606922 @default.
• W2118320211 hasAuthorship W2118320211A5027368636 @default.
• W2118320211 hasAuthorship W2118320211A5056278530 @default.
• W2118320211 hasAuthorship W2118320211A5090647064 @default.
• W2118320211 hasConcept C121608353 @default.
• W2118320211 hasConcept C126322002 @default.
• W2118320211 hasConcept C143998085 @default.
• W2118320211 hasConcept C167135981 @default.
• W2118320211 hasConcept C167734588 @default.
• W2118320211 hasConcept C2776694085 @default.
• W2118320211 hasConcept C2777025900 @default.
• W2118320211 hasConcept C2777802072 @default.
• W2118320211 hasConcept C2779490328 @default.
• W2118320211 hasConcept C50440223 @default.
• W2118320211 hasConcept C71924100 @default.
• W2118320211 hasConceptScore W2118320211C121608353 @default.
• W2118320211 hasConceptScore W2118320211C126322002 @default.
• W2118320211 hasConceptScore W2118320211C143998085 @default.
• W2118320211 hasConceptScore W2118320211C167135981 @default.
• W2118320211 hasConceptScore W2118320211C167734588 @default.
• W2118320211 hasConceptScore W2118320211C2776694085 @default.
• W2118320211 hasConceptScore W2118320211C2777025900 @default.
• W2118320211 hasConceptScore W2118320211C2777802072 @default.
• W2118320211 hasConceptScore W2118320211C2779490328 @default.
• W2118320211 hasConceptScore W2118320211C50440223 @default.
• W2118320211 hasConceptScore W2118320211C71924100 @default.
• W2118320211 hasLocation W21183202111 @default.
• W2118320211 hasLocation W21183202112 @default.
• W2118320211 hasOpenAccess W2118320211 @default.
• W2118320211 hasPrimaryLocation W21183202111 @default.
• W2118320211 hasRelatedWork W1902142936 @default.
• W2118320211 hasRelatedWork W2032051122 @default.
• W2118320211 hasRelatedWork W2034151655 @default.
• W2118320211 hasRelatedWork W2098870242 @default.
• W2118320211 hasRelatedWork W2119565846 @default.
• W2118320211 hasRelatedWork W2126958845 @default.
• W2118320211 hasRelatedWork W2513463504 @default.
• W2118320211 hasRelatedWork W2888246635 @default.
• W2118320211 hasRelatedWork W3023180431 @default.
• W2118320211 hasRelatedWork W3140687656 @default.
• W2118320211 isParatext "false" @default.
• W2118320211 isRetracted "false" @default.
• W2118320211 magId "2118320211" @default.
• W2118320211 workType "article" @default.